A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Pain [EXTENSION OF 700054125]
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Buprenorphine (Primary)
- Indications Back pain; Musculoskeletal pain; Neuropathic pain
- Focus Therapeutic Use
- Sponsors BioDelivery Sciences International
- 27 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.